Pharmacological Validation Phase Sample Clauses

Pharmacological Validation Phase. Each R&D Program shall also include a pharmacological validation phase, which includes ***, as applicable (“Stage 3 activities”). The Stage 3 activities for each R&D Program shall be referred to as the “Pharmacological Validation Phase” of the R&D Program. Prior to the initiation of Stage 3 activities for an R&D Program, *** (each, a “Pharmacological Validation Plan”), which shall include *** (“Stage 3 Clinical Trial Samples”) ***. The Pharmacological Validation Phase for each R&D Program and the R&D Program (unless terminated earlier) will terminate upon the earlier of: (i) receipt by GSK of KineMed’s analysis of the Stage 3 Clinical Samples resulting from a GSK clinical trial conducted by GSK in accordance with the applicable protocol for such clinical trial as described in the Pharmacological Validation Plan for such R&D Program (excluding any follow-up period for such clinical trial); and (ii) the termination of the clinical trial described in the Pharmacological Validation Plan for such R&D Program. EXECUTION COPY Confidential